免疫检查点抑制剂诱导的糖尿病 - - 一个简要的审查和三个病例报告
Marius-Lucian Mitrache1,2, Aura-Diana Reghina1,2, Iulia-Simona Stoian1,2
1Department of Endocrinology, Carol Davila University of Medicine and Pharmacy, 010825 Bucharest, Romania.
Journal of clinical medicine
|September 27, 2025
概括
免疫检查点抑制剂 (ICI) 可以引起与免疫相关的不良事件 (irAEs),包括ICI诱导的糖尿病 (ICI-DM). 这种情况是急性,可能危及生命,需要由瘤学家和内分泌学家进行仔细管理.
科学领域:
- 在瘤学瘤学.
- 内分泌学 在内分泌学.
- 免疫学 免疫学 免疫学
背景情况:
- 免疫检查点抑制剂 (ICI) 是重要的癌症治疗方法,但可能导致与免疫相关的不良事件 (irAEs).
- 越来越多的人认识到内分泌IRAE,包括ICI诱导的糖尿病 (ICI-DM).
- ICI-DM通常是急性,严重的,可能需要免疫治疗中断.
研究的目的:
- 要报告三起ICI-DM的病例.
- 审查关于ICI-DM的文献.
- 为管理ICI-DM分享临床见解.
主要方法:
- 案例系列呈现.
- 综合文献综述. 这是一个全面的文献综述.
主要成果:
- 随着ICI使用的扩大,ICI-DM发病率正在上升.
- 对ICI-DM的风险因素尚未完全描述.
- 由ICI-DM引起的内分泌功能障碍通常是不可逆转的.
结论:
- ICI-DM具有独特的急性,严重和可能危及生命的症状.
- 管理需要瘤学家和内分泌学家之间的合作.
- 在ICI-DM中,常常需要终身激素替代疗法.
相关概念视频
Dipeptidyl Peptidase 4 Inhibitors
594
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
594
Diabetes Mellitus: Overview and Type I Subtype
4.9K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
4.9K
Oral Hypoglycemic Agents: Biguanides and Glitazones
585
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
585
Diabetes Mellitus: Type 2 and Gestational
4.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.3K
Diabetes: Symptoms, Diagnosis, and Complications
2.1K
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
2.1K
Insulin: Dosing Regimen and Adverse Effects
685
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
685


